Proliferative Vitreoretinopathy (PVR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Proliferative Vitreoretinopathy (PVR) Market Outlook
Thelansis’s “Proliferative
Vitreoretinopathy (PVR) Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Proliferative
Vitreoretinopathy (PVR) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
Proliferative
Vitreoretinopathy (PVR) Overview
Proliferative
vitreoretinopathy (PVR) is the most common cause of failure of rhegmatogenous
retinal detachment repair. It is characterised by the growth and contraction of
cellular membranes within the vitreous cavity and on both sides of the retinal
surface and intraretinal fibrosis. Contraction of these membranes can cause the
retina to redetach and transform a rhegmatogenous detachment into a tractional
detachment. It is most common as a clinical complication of surgical procedures
to correct rhegmatogenous retinal detachments, which are detachments that
follow the formation of a retinal tear or hole. Tractional forces produced by
the scar tissue-like PVR membranes can be transmitted to the retina, resulting
in complete retinal detachment, retinal degeneration, and permanent blindness.
PVR has also been reported to be common following posterior segment procedures
or disorders such as giant retinal tears, macular relocation surgery, tumors
endoresection, and chip implantation. PVR has been developed in 29% of
cytomegalovirus retinitis-related retinal detachment patients infected with the
human immunodeficiency virus.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment